Biograph Vision vs Lung AI

Similar category, different focus. These tools serve overlapping but distinct needs. Comparability 65/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.

Biograph Vision

by Siemens Healthineers

Lung AI

by Multiple (e.g., RevealDx, Optellum, LungLife AI, Qure.ai, Arterys, DeepHealth, HeartLung.AI)

AI Verdict

While both tools leverage AI for medical imaging in cardiology and radiology, they serve distinct purposes. Biograph Vision is a high-end PET/CT system for detailed diagnostic imaging in specialized departments, focusing on precision and comprehensive analysis. Lung AI, conversely, is a handheld ultrasound platform designed for real-time, point-of-care assessment, prioritizing accessibility and rapid decision-making in emergency medicine and pulmonology.

Choose Biograph Vision if…

Choose Biograph Vision if your facility requires a high-precision, dedicated PET/CT system for detailed diagnostic imaging in oncology, cardiology, and neurology. This tool excels in providing ultra-high resolution and sensitivity, enabling faster scans with lower radiopharmaceutical doses for comprehensive patient evaluation in a specialized imaging department.

View Biograph Vision →

Choose Lung AI if…

Choose Lung AI if your clinical setting demands a portable, real-time AI-powered ultrasound solution for rapid point-of-care diagnostics, particularly in emergency medicine, pulmonology, or cardiology. Its on-device AI processing and guided image capture empower healthcare professionals to make immediate, critical decisions at the patient's bedside, even in environments without internet access.

View Lung AI →

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Quick Comparison

Feature	Biograph Vision	Lung AI
Deployment	On-premise (medical imaging system)	Cloud-based, integrated with existing platforms (e.g., RapidAI), and potentially on-premise.
FDA Status	Yes AI-estimated	Cleared AI-estimated
HIPAA	Yes AI-estimated	Yes AI-estimated

Head-to-Head

AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.

Usability

Lung AI

Tool B (Lung AI) is designed as a handheld ultrasound platform emphasizing 'easy-to-use' features and 'guided image capture,' making it highly accessible for real-time decisions at the point of care. In contrast, Tool A (Biograph Vision) is a complex, on-premise PET/CT system requiring specialized training and a dedicated facility, despite its features for patient comfort and reduced scan times.

Clinical Value

Tie

Both tools offer significant clinical value in their respective domains. Tool A provides high-resolution, precise diagnostics for complex conditions in oncology, cardiology, and neurology, offering deep insights. Tool B enables critical, real-time decisions at the point of care through AI-powered detection for lung and cardiac conditions, directly impacting immediate patient outcomes.

Pricing & Value

Lung AI

Tool B (Lung AI) explicitly aims to deliver 'affordable, easy-to-use medical imaging,' suggesting a lower entry cost and broader accessibility for various healthcare settings. Tool A (Biograph Vision) is a high-end PET/CT system, which inherently represents a substantial capital investment, with pricing available only upon vendor contact.

Enterprise Readiness

Lung AI

Tool B (Lung AI) explicitly states HIPAA compliance and offers a Business Associate Agreement (BAA), which are crucial for enterprise data privacy and security. Its on-device AI processing also allows for operation without internet, enhancing deployment flexibility. While Tool A's *use* must comply with HIPAA, the device itself does not offer a BAA or direct HIPAA compliance in the same manner as a software solution.

Innovation

Lung AI

Tool B (Lung AI) demonstrates disruptive innovation by integrating AI into an affordable, handheld ultrasound platform for real-time diagnostics and therapeutic applications, democratizing access to advanced imaging. While Tool A (Biograph Vision) advances high-end diagnostic imaging with cutting-edge detector technology and performance, Tool B's approach offers a broader impact on healthcare delivery through accessibility and point-of-care integration.

Support & Docs

Lung AI

Tool B (Lung AI) explicitly lists 'Exo U (AI-powered POCUS education and training)' as a key feature, directly demonstrating a proactive approach to user enablement and ongoing support. While Tool A (Biograph Vision), as a Siemens Healthineers product, would undoubtedly have comprehensive support, this is not explicitly detailed in the provided facts.

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature	Biograph Vision	Lung AI
Product Type	PET/CT imaging system	Handheld ultrasound platform
Company	Siemens Healthineers	Exo
Primary Specialties	Nuclear Medicine, Oncology, Radiology	Cardiology, Emergency Medicine, Pulmonology
Key AI Capabilities	OncoFreeze and CardioFreeze for motion correction	AI-powered detection of pleural effusion, AI-powered detection of consolidation/atelectasis, Automated AI-based indicators for cardiac conditions
Core Imaging Technology	Optiso Ultra Dynamic Range (UDR) detector technology with 3.2-mm LSO crystals and SiPMs, 214-ps true time-of-flight (TOF) performance	Handheld ultrasound with Pulsed-wave Doppler capabilities (on Exo Iris)

Videos

Demos, reviews, and walkthroughs featuring Biograph Vision and Lung AI.

Loading videos…

Videos need JavaScript to load. Search YouTube directly →

View all on YouTube

Frequently Asked Questions

How do these tools integrate into existing clinical workflows and what is their primary clinical context?

Biograph Vision is a fixed PET/CT system designed for detailed diagnostic imaging in specialized departments like oncology, cardiology, and neurology, aiming to reduce scan times and patient dose for comprehensive examinations. Lung AI, integrated with the Exo Iris handheld ultrasound, is a portable solution for real-time, point-of-care diagnostics, empowering healthcare professionals to make critical decisions at the bedside, particularly in cardiology, emergency medicine, and pulmonology.

What is the expected learning curve for physicians and staff, and how quickly can each system deliver clinical value?

Biograph Vision, as a sophisticated PET/CT system, typically requires specialized training for operation and interpretation, delivering long-term diagnostic value through high-precision imaging. Lung AI, with its handheld design, AI-guided image capture, and integrated educational platform (Exo U), aims for a faster adoption curve, enabling quicker acquisition of diagnostic information and immediate point-of-care clinical value, even for less experienced users.

What are the key differences in accuracy and sensitivity for their respective clinical applications?

Biograph Vision offers high resolution, sensitivity, and ultra-fast time-of-flight performance for precise diagnostics, enabling detection of small lesions and improved image quality in oncology, cardiology, and neurology. Lung AI provides AI-powered detection of pleural effusion and consolidation/atelectasis, along with automated indicators for cardiac conditions, with studies showing improved accuracy and sensitivity for clinicians, particularly benefiting less experienced users.

Beyond standard data privacy, what specific security and audit-trail features do these tools offer?

Biograph Vision systems with AIDAN offer enhanced protection against cyber threats via syngo Security, a package for general regulatory security rules. For Lung AI, the on-device AI processing means it operates without internet connectivity for core functions, and Exo emphasizes a robust cloud and application Privacy by Design program, with audit trails for AI model versions and prompts.

How do multi-site rollout considerations differ for these two systems?

Biograph Vision, as a large, on-premise PET/CT system, typically involves significant infrastructure and specialized installation for each site, making multi-site rollout a more centralized and capital-intensive endeavor. In contrast, Lung AI's handheld, on-device nature and affordability suggest a more decentralized and potentially easier multi-site rollout, enabling broader access to AI-powered ultrasound across various care settings, including rural or under-resourced areas.

What level of EHR integration depth can be expected for each tool, particularly for image transfer and AI-derived insights?

Biograph Vision integrates with PACS/RIS systems, facilitating image transfer and subsequent integration into EHRs, with features like PET FAST Workflow AI automating post-scan tasks and data export. Lung AI, as a handheld device, would likely transfer images and AI-derived insights to EHRs via its associated workflow software, Exo Works, or other digital means, allowing for real-time data acquisition and interpretation at the point of care.